https://www.selleckchem.com/pr....oducts/tunicamycin.h
d intervention across both conditions. In this large and geographically broad US based cohort, CV risk for T2DM patients was elevated, as was the risk for patients with prior CV events, while patients with T2DM plus prior CV events had the highest risk of future CV events. The substantial clinical and economic burden of CV events and HF in patients with both T2DM and prior CV events suggest a need for an integrated treatment and targeted intervention across both conditions.There is considerable industry excitement about the curative
Like
Comment
Share
